LXG.V - LexaGene Holdings Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.9300
-0.0200 (-2.11%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.9500
Open0.9400
Bid0.9200 x 0
Ask0.9300 x 0
Day's Range0.9200 - 0.9500
52 Week Range0.4300 - 1.0000
Volume121,612
Avg. Volume147,049
Market Cap83.268M
Beta (5Y Monthly)2.41
PE Ratio (TTM)N/A
EPS (TTM)-0.0980
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    LexaGene to Host Webcast on July 14, 2020

    LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops genetic analyzers for rapid pathogen detection, is pleased to announce that it will host a webcast investor presentation on Tuesday, July 14, at 2:00 PM ET. During the webcast, Dr. Jack Regan, LexaGene’s CEO and Founder, will provide an introductory presentation through a PowerPoint discussion that will cover key areas of LexaGene’s business, including an overview of the Company’s proprietary technology, target markets and opportunity, competitive advantages, growth strategy, and anticipated milestones. Following the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal.

  • GlobeNewswire

    LexaGene to Present at Lytham Partners Virtual Investor Growth Conference

    LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection, is scheduled to participate in a virtual presentation and fireside chat at the Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 1:00pm ET (10:00am PT). A webcast of the presentation will be posted under the investor relations section of LexaGene’s website at www.lexagene.com, or can be accessed at https://www.webcaster4.com/Webcast/Page/2419/35342  or www.lythampartners.com/virtual. To arrange a meeting, please contact Joe Dorame of Lytham Partners at dorame@lythampartners.com or visit www.lythampartners.com/virtual.

  • GlobeNewswire

    LexaGene Provides Status Update on COVID-19 Testing at a Major Hospital Laboratory

    LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, is pleased to provide a status update on the previously announced placement of its pre-commercial LX Analyzer. The instrument the Company placed in a major US hospital laboratory was configured to screen for COVID-19 and seven other respiratory pathogens. LexaGene’s technology performs highly multiplex RT-PCR, which is a gold-standard chemistry that provides exceptional sensitivity and specificity.

  • Newsfile

    LexaGene Holdings, Inc. Discusses the Sales Strategy for Its Pathogen Detection Technology with the Stock Day Podcast

    Phoenix, Arizona--(Newsfile Corp. - June 11, 2020) - The Stock Day Podcast welcomed LexGene Holdings, Inc. (TSXV: LXG) (OTCQB: LXXGF) (the "Company"), a biotechnology company that develops genetic analyzers for rapid pathogen detection is pleased to provide the following update on the Company's development plans of its flagship pathogen detection platform for the human clinical, veterinary diagnostics, and food safety sectors. President of the Company, Daryl Rebeck, joined Stock Day host Everett Jolly.Rebeck began ...

  • The Global Race for Testing and Vaccines for COVID-19 Sees Biotechnology Innovation at its Best
    Newsfile

    The Global Race for Testing and Vaccines for COVID-19 Sees Biotechnology Innovation at its Best

    Point Roberts, Washington and Delta, British Columbia--(Newsfile Corp. - June 3, 2020) - Investor Ideas, a global investor news source covering biotech and pharma stocks releases a COVID-19 sector snapshot. According to Bio.org, COVID-19 (Coronavirus) has ignited the sector, noting "Biotech Companies are responding faster than ever to emerging health threats." Investor ideas looks at some of the leading innovators and what is in the pipeline.Read the full article/snapshot looking at biotech stocks:https://www.investorideas.com/News/2020/biotech/06030Vaccines-Covid19.aspLexaGene Holdings, ...

  • GlobeNewswire

    LexaGene Provides Update on Commercializing its Automated Pathogen Detection System

    LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”) a biotechnology company that develops genetic analyzers for rapid pathogen detection is pleased to provide the following update on the Company’s development plans of its flagship pathogen detection platform for the human clinical, veterinary diagnostics, and food safety sectors. As previously announced, LexaGene has recently placed a pre-commercial unit of its LX Analyzer in a major US hospital laboratory for the testing of COVID-19 and has submitted its plan to the FDA for Emergency Use Authorization (EUA).

  • GlobeNewswire

    LexaGene Places a Pre-Commercial Instrument for COVID-19 Testing in a Major Hospital Laboratory

    LexaGene Holdings, Inc. (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, is pleased to announce the placing of a pre-commercial instrument that tests for COVID-19 and other respiratory pathogens at the Dartmouth-Hitchcock Medical Center (DHMC) in their Laboratory for Clinical Genomics and Advanced Technology (CGAT) in Hanover, New Hampshire. Given the highly contagious nature of this virus, this is a long time to wait.

  • GlobeNewswire

    LexaGene Holdings Receives Approval to Amend Warrant Terms

    LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”) announces that further to its April 29, 2020 press release, it has received approval from the TSX Venture Exchange to amend the exercise price of the common share purchase warrants (the “Warrants”) issued on March 29, 2019. In connection with a $2.65 million offering of units (net of costs), 4,375,271 Warrants were issued with an exercise price of $0.85 per common share of LexaGene (a “Common Share”). The Company originally announced that it had intended to amend the exercise price of the Warrants to $0.60 per Common Share and amend the terms of the acceleration clause; the Company has since received approval to amend the exercise price of the Warrants to $0.65 per Common Share.

  • GlobeNewswire

    LexaGene Holdings Proposes to Amend Warrants Terms and Announces a Strategic Marketing Promotional Campaign

    LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”) announces that it intends to amend the exercise price of the common share purchase warrants (the “Warrants”) issued on March 29, 2019. In connection with a $2.65 million offering of units (net of costs), 4,634,686 Warrants were issued with an exercise price of $0.85 per common share of LexaGene (a “Common Share”).

  • LexaGene CEO Discusses COVID-19 Testing, Commercialization Strategy -- SECFilings.com
    Newsfile

    LexaGene CEO Discusses COVID-19 Testing, Commercialization Strategy -- SECFilings.com

    Redondo Beach, California--(Newsfile Corp. - April 16, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an interview with Dr. Jack Regan, CEO and Founder of LexaGene Holdings Inc. (OTCQB: LXXGF) (TSX-V: LXG), discussing the company's development of genetic analyzers capable of quickly and accurately detecting pathogens, including COVID-19. Dr. Regan has an extensive background in virology, and particularly respiratory pathogens ...

  • GlobeNewswire

    LexaGene Files Patent Application for Expanded Capabilities of Their LX Analyzer

    LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today the filing of a provisional patent application to the United States Patent and Trademark Office to protect the expanded testing capabilities of their LX Analyzer technology, as it relates to COVID-19 and other clinical laboratory testing, as well as other high-throughput applications such as food safety testing. LexaGene plans to launch its multiplex, PCR-based LX Analyzer as its flagship product, targeting decentralized testing facilities in the clinical, veterinary, and food safety markets during Q3 of this year.

  • Does LexaGene Holdings Inc. (CVE:LXG) Have A Particularly Volatile Share Price?
    Simply Wall St.

    Does LexaGene Holdings Inc. (CVE:LXG) Have A Particularly Volatile Share Price?

    If you're interested in LexaGene Holdings Inc. (CVE:LXG), then you might want to consider its beta (a measure of share...

  • GlobeNewswire

    LexaGene Appoints Dr. Eleanor Kolossovski to Director of Product Marketing

    LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, today announced the appointment of Dr. Eleanor Kolossovski to the role of Director of Product Marketing. Dr. Kolossovski will help lead the development and execution of LexaGene’s go-to-market strategy for the LX Analyzer, as well as build brand awareness and thought leadership to propel significant growth opportunities in clinical diagnostics, veterinary diagnostics, food safety testing, and other applied market segments.

  • GlobeNewswire

    LexaGene Appoints Steven Armstrong to Senior Director of Operations

    LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, today announced the appointment of Mr. Steven Armstrong to the role of Senior Director of Operations to oversee the Company’s submission for FDA Emergency Use Authorization of its commercial technology and other regulatory approvals, as well as to institute quality systems for manufacturing. Mr. Armstrong has spent his career leading numerous teams in the commercialization of complex medical devices, directly overseeing global operations including design, development, manufacturing and service operations in eight countries.

  • GlobeNewswire

    LexaGene Provides Update on the Exercise of Warrants

    LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, today announces that it has received proceeds from the exercise of warrants. LexaGene is pleased to report that over the past 90 days the Company has received CAD $2.8 million through the exercise of 4.3 million warrants.

  • GlobeNewswire

    LexaGene Provides Corporate Update

    LexaGene Holdings, Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, provides the following corporate update on the development of its commercial technology and information on how the Company has responded to the demand for its technology in view of the COVID-19 outbreak. In response to the COVID-19 outbreak, the World Health Organization has declared a ‘Public Health Emergency of International Concern’ and the FDA has encouraged CLIA labs and IVD manufacturers to submit applications for Emergency Use Authorization (EUA) to help address the lack of quality diagnostics to fight this disease.

  • Coronavirus Highlights Need for Rapid Testing of Pathogens -- SECFilings.com
    Newsfile

    Coronavirus Highlights Need for Rapid Testing of Pathogens -- SECFilings.com

    Seattle, Washington--(Newsfile Corp. - March 9, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing how LexaGene Holdings Inc. (OTCQB: LXXGF) (TSXV: LXG) is focused on making testing for pathogens quicker and easier than ever before.A California woman was identified, on February 26, 2020, as the first U.S. resident to contract the coronavirus (COVID-19) from an unknown source. ...

  • GlobeNewswire

    LexaGene’s LX Analyzer Successfully Detects Coronavirus RNA using the CDC’s Tests

    BEVERLY, Mass., Feb. 20, 2020 -- LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a biotechnology company that develops genetic analyzers for.

  • Newsfile

    LexaGene Discusses The Company's 2020 Commercialization Strategy with The Stock Day Podcast

    Phoenix, Arizona--(Newsfile Corp. - January 28, 2020) - The Stock Day Podcast welcomed LexaGene Holdings Inc. (OTCQB: LXXGF) ("the Company"), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. CEO and Founder of the Company, Dr. Jack Regan, joined Stock Day host Everett Jolly. Dr. ...

  • GlobeNewswire

    LexaGene’s Analyzer is Designed to Detect Pathogens such as the Novel Coronavirus to Help Avert a Pandemic

    BEVERLY, Mass., Jan. 27, 2020 -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a biotechnology company that develops genetic analyzers for.

  • GlobeNewswire

    Newly-developed Tests Achieve 100% Concordance on Superbug Strains from the CDC

    LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today it has expanded its number of validated tests for antibiotic resistance and has completed testing different superbug isolates provided by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) Antibiotic Resistance (AR) Isolate Bank.

  • LexaGene Holdings (CVE:LXG) Shares Have Generated A Total Return Of 126% In The Last Three Years
    Simply Wall St.

    LexaGene Holdings (CVE:LXG) Shares Have Generated A Total Return Of 126% In The Last Three Years

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    LexaGene Announces Closing of CAD$6.64 Million Financing

    LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") is pleased to announce that it has closed its previously announced offering of units (the “Units”) for aggregate gross proceeds of CAD$6.64 million (the “Offering”). The Company issued 12,769,626 Units at a price of CAD$0.52 per Unit, each Unit consisting of one common share of the Company (a “Share”) and one common share purchase warrant, with each warrant entitling the holder to purchase one Share at the price of CAD$0.75 per Share until October 29, 2022. The Offering was conducted by Industrial Alliance Securities Inc. (the “Agent”).

  • LexaGene Holdings Announces Filing of Final Prospectus
    CNW Group

    LexaGene Holdings Announces Filing of Final Prospectus

    BEVERLY, MA, Oct. 22, 2019 /CNW/ - LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") is pleased to announce that it has filed and received a receipt for a final short form prospectus (the "Prospectus") dated October 21, 2019 with the securities regulatory authorities in each of the provinces of Canada, except the Province of Quebec, in connection with the previously announced marketed offering of units (the "Units") of a minimum amount of C$3,500,000 and a maximum of C$10,000,000 at the price of C$0.52 per Unit (the "Offering"). The Offering is being conducted on a "best efforts" agency basis by Industrial Alliance Securities Inc., the Company's agent for the Offering in Canada (the "Agent"). The Units may also be offered for sale in the United States on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and applicable state laws and in such other jurisdictions outside of Canada and the United States as agreed between the Company and the Agent.

  • GlobeNewswire

    LexaGene Holdings Announces Pricing of Prospectus Offering

    LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") is pleased to announce today the pricing of its marketed public offering, which was previously announced in a press release dated September 24, 2019 (the “Offering”). The Company will offer a minimum of 6,730,770 units of the Company (each a “Unit”) and a maximum of 19,230,769 Units at the price of $0.52 per Unit for minimum gross proceeds of approximately $3,500,000 and maximum gross proceeds of approximately $10,000,000. Each Unit is comprised of one common share in the capital of the Company (a “Unit Share”) and one common share purchase warrant (a “Warrant”).